Cargando…

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab

The aim of our study was to investigate whether microRNAs (miRNAs) could serve as predictive biomarkers to anti-EGFR therapy (cetuximab, panitumumab) in patients with RAS wild-type (wt-RAS) metastatic colorectal cancer (mCRC). Historical cohort of 93 patients with mCRC (2006–2009) was included and f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mlcochova, Jitka, Faltejskova-Vychytilova, Petra, Ferracin, Manuela, Zagatti, Barbara, Radova, Lenka, Svoboda, Marek, Nemecek, Radim, John, Stanislav, Kiss, Igor, Vyzula, Rostislav, Negrini, Massimo, Slaby, Ondrej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770730/ https://www.ncbi.nlm.nih.gov/pubmed/26497852

Ejemplares similares

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy
por: Nemecek, Radim, et al.
Publicado: (2016)

Identification and functional screening of microRNAs highly deregulated in colorectal cancer
por: Faltejskova, Petra, et al.
Publicado: (2012)

Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer
por: Thorenoor, Nithyananda, et al.
Publicado: (2015)

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients
por: Lupini, Laura, et al.
Publicado: (2015)

MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9
por: Vychytilova-Faltejskova, Petra, et al.
Publicado: (2017)

Common polymorphisms in GSTM1, GSTT1, GSTP1, GSTA1 and susceptibility to colorectal cancer in the Central European population
por: Hezova, Renata, et al.
Publicado: (2012)

MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma
por: Vychytilova-Faltejskova, Petra, et al.
Publicado: (2015)

Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma
por: Redova, Martina, et al.
Publicado: (2012)

MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients
por: Svoboda, Marek, et al.
Publicado: (2012)

miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib
por: Merhautova, Jana, et al.
Publicado: (2015)

Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
por: GRELL, PETER, et al.
Publicado: (2012)

MiR-215-5p Reduces Liver Metastasis in an Experimental Model of Colorectal Cancer through Regulation of ECM-Receptor Interactions and Focal Adhesion
por: Machackova, Tana, et al.
Publicado: (2020)

A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein
por: Valianatos, Georgios, et al.
Publicado: (2017)

MicroRNAs in colorectal cancer: translation of molecular biology into clinical application
por: Slaby, Ondrej, et al.
Publicado: (2009)

Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma
por: Mlcochova, Hana, et al.
Publicado: (2016)

Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer
por: Slaby, Ondrej, et al.
Publicado: (2012)

MicroRNA Biogenesis Pathway Genes Are Deregulated in Colorectal Cancer
por: Vychytilova-Faltejskova, Petra, et al.
Publicado: (2019)

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX
por: Kiss, I., et al.
Publicado: (2017)

Novel classes of non-coding RNAs and cancer
por: Sana, Jiri, et al.
Publicado: (2012)

Decreased expression levels of PIWIL1, PIWIL2, and PIWIL4 are associated with worse survival in renal cell carcinoma patients
por: Iliev, Robert, et al.
Publicado: (2016)

MiR-34b is associated with clinical outcome in triple-negative breast cancer patients
por: Svoboda, Marek, et al.
Publicado: (2012)

MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications
por: Sana, Jiri, et al.
Publicado: (2011)

Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy
por: Slaby, Ondrej, et al.
Publicado: (2010)

Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy
por: Slaby, Ondrej, et al.
Publicado: (2010)

MicroRNA isolation and quantification in cerebrospinal fluid: A comparative methodical study
por: Kopkova, Alena, et al.
Publicado: (2018)

Identification of microRNA signatures in umbilical cord blood associated with maternal characteristics
por: Juracek, Jaroslav, et al.
Publicado: (2019)

LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
por: Bútová, Romana, et al.
Publicado: (2021)

Epigenetic Regulation of MicroRNA Clusters and Families during Tumor Development
por: Gregorova, Jana, et al.
Publicado: (2021)

Genome‐wide identification of urinary cell‐free microRNAs for non‐invasive detection of bladder cancer
por: Juracek, Jaroslav, et al.
Publicado: (2018)

Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma
por: Vlachová, Monika, et al.
Publicado: (2022)

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
por: Lakomy, Radek, et al.
Publicado: (2017)

Long Non-Coding RNAs in Multiple Myeloma
por: Butova, Romana, et al.
Publicado: (2019)

FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer
por: Grell, Peter, et al.
Publicado: (2023)

Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer
por: Koleckova, Marketa, et al.
Publicado: (2021)

p16, HPV, and Cetuximab: What Is the Evidence?
por: Bonner, James A., et al.
Publicado: (2017)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
por: Alonso, Vicente, et al.
Publicado: (2018)

The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
por: Ziranu, Pina, et al.
Publicado: (2021)

Identification of microRNAs differentially expressed in glioblastoma stem-like cells and their association with patient survival
por: Sana, Jiri, et al.
Publicado: (2018)

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
por: Bencsikova, Beatrix, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i0s810pco5t6l5ucujal5904d7